Vaxxas Revenue and Competitors

Sydney, AUS

Location

$46.2M

Total Funding

Industry

Estimated Revenue & Valuation

  • Vaxxas's estimated annual revenue is currently $15M per year.(i)
  • Vaxxas's estimated revenue per employee is $98,039
  • Vaxxas's total funding is $46.2M.

Employee Data

  • Vaxxas has 153 Employees.(i)
  • Vaxxas grew their employee count by 13% last year.

Vaxxas's People

NameTitleEmail/Phone
1
Chief Operating OfficerReveal Email/Phone
2
Chief Financial OfficerReveal Email/Phone
3
Chief Technology OfficerReveal Email/Phone
4
Chief Business Officer/General Counsel/EVPReveal Email/Phone
5
Head Manufacturing and Operational ExcellenceReveal Email/Phone
6
Head Formulation & AnalyticalReveal Email/Phone
7
Head, Special ProjectsReveal Email/Phone
8
SVP Vaccine AlliancesReveal Email/Phone
9
Head Early-Stage & Preclinical R&DReveal Email/Phone
10
SVP QualityReveal Email/Phone

What Is Vaxxas?

Vaxxas is a company based out of Vaxxas Pty Ltd (ACN 152 205 242)c/- OneVentures Management Suite 304, Level 3, 1 Alfred Street, Sydney, NSW, Australia.

keywords:N/A

$46.2M

Total Funding

153

Number of Employees

$15M

Revenue (est)

13%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Vaxxas News

2022-04-17 - Vaxxas Announces Appointment of Scott Fry Ph.D. as Chief ...

CAMBRIDGE, Mass. & BRISBANE, Australia--(BUSINESS WIRE)--Apr 20, 2022--. Vaxxas, a clinical-stage biotechnology company commercializing a...

2022-03-30 - Vaxxas strikes deal to tee up trial of COVID-19 vaccine patch

Massachusetts-based Vaxxas has a patch delivery technology, HD-MAP, that uses an array of projections to get vaccines to immune cells below the surface of the...

2022-03-22 - Vaxxas obtains licence for needle-free Covid-19 vaccine from UT ...

Vaxxas has obtained an exclusive license to the SARS-CoV-2 spike subunit vaccine, HexaPro, from The University of Texas at Austin (UT...

2015-02-10 - Vaxxas $20M in Series B Venture Financing

Vaxxas, a Cambridge, Mass., USA, and Brisbane, Queensland, Australia-based biotechnology company commercializing a novel vaccination platform, secured A$25m [US$20m] series B equity funding. New and existing investors participated. This new round brought the total capital raised to A$40m [US$33 ...

2015-02-10 - Vaxxas gets $20M for vaccine that can be worn as a patch

Vaxxas plans to apply its patented patch technology to develop new vaccine forms for influenza, polio, bacterial infections and cancer. It already has collaborations underway with Merck to develop its Nanopatch for undisclosed vaccine candidates. The Series B round was led by Australian investm ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$32.2M1539%N/A
#2
$32.8M15420%N/A
#3
$41.7M15423%N/A
#4
$16.2M15527%N/A
#5
$14.9M15560%N/A